If you want the broader landscape (and the list of other peptides driving search interest), see Metos internal piece: 14 Peptides Are About to Become Legal Again What This Means for Your Health. Who should consider AOD-9604 (and who shouldnt) Consider it only if your expectations are realistic AOD-9604 may be worth a conversation if you are: Already doing the fundamentals (protein, resistance training, sleep) Not seeking massive scale weight loss Looking at fat-loss support rather than appetite suppression Intolerant of GLP-1s and exploring alternatives (with the understanding that alternatives are usually less powerful) Avoid it if You have significant obesity and need a high-efficacy therapy (GLP-1/GIP class is typically far more impactful) (PubMed) Youre hoping it will melt fat without dietary alignment Your plan depends on unverified sources or research peptide suppliers Youre in a drug-tested sport environment (WADA prohibition is relevant) (wada-ama.org) Practical expectations (what most people want to know) How fast does it work
The clinic initially offered liraglutide, but it was hard to find on the site, and semaglutide was still listed even after it had been discontinued
NICE guidance and NHS resources provide a robust framework for sustainable weight management that does not rely on investigational pharmacology
(2005) Recombinant, nonglycosylated human insulin-like growth factor-binding protein-3 (IGFBP-3) is degraded preferentially after administration to type II diabetics, resulting in increased endogenous glycosylated IGFBP-3
Haematological responses typically occur within 1-2 weeks, but neurological recovery may take months and can be incomplete if the deficiency has been prolonged
X., et al
